Compare ACRS & OWLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACRS | OWLS |
|---|---|---|
| Founded | 2012 | 2010 |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 608.9M | 508.2M |
| IPO Year | 2015 | N/A |
| Metric | ACRS | OWLS |
|---|---|---|
| Price | $5.71 | $5.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $10.20 | ★ $11.00 |
| AVG Volume (30 Days) | ★ 2.0M | 22.4K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.01 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,683,000.00 | N/A |
| Revenue This Year | N/A | $6.57 |
| Revenue Next Year | $4.24 | $375.69 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.46 | $5.15 |
| 52 Week High | $5.76 | $29.00 |
| Indicator | ACRS | OWLS |
|---|---|---|
| Relative Strength Index (RSI) | 71.95 | 47.84 |
| Support Level | $4.13 | $5.50 |
| Resistance Level | N/A | $6.14 |
| Average True Range (ATR) | 0.31 | 0.14 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 92.26 | 65.85 |
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
OBOOK Holdings Inc is focused on using blockchain technology to provide inventive solutions to customers in various sectors, including financial services, hospitality, and e-commerce. Through its e-commerce, hospitality and payments offerings, it is committed to serving businesses and individuals whose commercial activities involve cross-border transactions.